A research group led by Claus M. Azzalin at iMM has discovered that a human enzyme named FANCM is absolutely required for the survival of ALT tumor cells. The results were now published in the open access journal Nature Communications. Future strategies targeting the activity of this molecule in ALT tumor cells can constitute the basis of a novel therapeutic protocol for the treatment of these tumors.
